Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.50 |
| ▸ | RORC | P51449 | 4/20 | 0.47 |
| ▸ | JAK2 | O60674 | 1/20 | 0.43 |
| ▸ | JAK1 | P23458 | 1/20 | 0.43 |
| ▸ | USP30 | Q70CQ3 | 4/20 | 0.42 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | NAMPT | P43490 | 1/20 | 0.41 |
| ▸ | LIPE | Q05469 | 1/20 | 0.40 |
| ▸ | TACR1 | P25103 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3177397 | 1.00 | GPR119 (0.50) | GPR119RORCJAK2JAK1USP30 | |
| SCHEMBL13461072 | 1.00 | GPR119 (0.50) | GPR119RORCJAK2JAK1USP30 | |
| SCHEMBL5520664 | 0.88 | HDAC1 (0.48) | GPR119RORCUSP30NR1H2LIPE | |
| SCHEMBL5522852 | 0.88 | HDAC1 (0.48) | GPR119RORCUSP30NR1H2LIPE | |
| SCHEMBL10068041 | 0.86 | GPR119 (0.46) | GPR119RORCJAK2JAK1USP30 | |
| SCHEMBL707043 | 0.86 | GPR119 (0.46) | GPR119RORCJAK2JAK1USP30 | |
| SCHEMBL10038438 | 0.86 | GPR119 (0.46) | GPR119RORCJAK2JAK1USP30 | |
| SCHEMBL2800431 | 0.82 | RAB9A (0.37) | — | |
| SCHEMBL5025626 | 0.82 | RAB9A (0.37) | — | |
| SCHEMBL20031547 | 0.80 | NR1H2 (0.53) | GPR119USP30NR1H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7683068-B2 | Hydroisoindoline tachykinin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2010-03-23 | — | — | US | disclosed |
| US-7645790-B2 | Hydroisoindoline tachykinin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2010-01-12 | — | — | US | disclosed |
| US-20090054462-A1 | Hydroisoindoline tachykinin receptor antagonists | MERCK SHARP & DOHME CORP. | 2009-02-26 | — | — | US | disclosed |
| US-20080280966-A1 | Hydroisoindoline Tachykinin Receptor Antagonists | VYNE THERAPEUTICS INC. (F/K/A MENLO THERAPEUTICS INC. AND SUCCESSOR-IN-INTEREST TO VYNE PHARMACEUTICALS LTD., F/K/A FOAMIX PHARMACEUTICALS LTD.) | 2008-11-13 | — | — | US | disclosed |
| US-7345083-B2 | Hydroisoindoline tachykinin receptor antagonists | MERCK & CO., INC. (US) | 2008-03-18 | — | — | US | disclosed |
| US-20070161695-A1 | Hydroisoindoline tachykinin receptor antagonists | VYNE THERAPEUTICS INC. (F/K/A MENLO THERAPEUTICS INC. AND SUCCESSOR-IN-INTEREST TO VYNE PHARMACEUTICALS LTD., F/K/A FOAMIX PHARMACEUTICALS LTD.) | 2007-07-12 | — | — | US | disclosed |
| US-7217731-B2 | Hydroisoindoline tachykinin receptor antagonists | MERCK & CO., INC. (US) | 2007-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054462-A1 | Hydroisoindoline tachykinin receptor antagonists | TACR1, TACR2, NPSR1 | GPR119 440/4885RORC 2600/4885JAK2 902/4885 |
| US-20070161695-A1 | Hydroisoindoline tachykinin receptor antagonists | TACR1, TACR2, NPSR1 | GPR119 440/4885RORC 2600/4885JAK2 902/4885 |
| US-20080280966-A1 | Hydroisoindoline Tachykinin Receptor Antagonists | TACR1, TACR2, NPSR1 | GPR119 364/4885RORC 2807/4885JAK2 1011/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.